Maladie de Parkinson : Servier et Oncodesign annoncent la sélection d’un candidat préclinique
Initiée en mars 2019, cette collaboration de Recherche et Développement porte sur la découverte d’inhibiteurs de la kinase LRRK2 issus de la plateforme Nanocyclix®, propriété d’Oncodesign, et sur leur action comme agents thérapeutiques potentiels contre la maladie de Parkinson.
Christophe Parsy, PhD, Drug Discovery Business Development Director 2 April 2020 17h-17h45 – Paris & 11h-11h45 – New York 7 April 2020 20h-20h45 – Paris & 11h-11h45 – San Diego
Outsourcing drug discovery has become an overwhelmingly accepted approaches across the pharmaceutical industry from virtual biotech to large pharmaceutical companies as part of the globalization process. It does represent a cost-effective opportunity to access specialized technologies and expert scientist resources having a broad knowledge of pharmaceutical drug discovery development.
When it comes to outsourcing a project, quality, innovation, time and agility are key components of the selection process to build a trusted and long term relationship.
Key learning objectives
Introduction to a solution provider from hits finding to IND
Advantages of Drug discovery integrated provider vs silos approach
About our speaker Christophe Parsy
Christophe has acquired a broad knowledge of the pharmaceutical industry by working in various R&D environments from Research services provider to Biotech and large Pharma. Over the past 20 years, he lead major drug discovery projects from Hit to IND in Anti-infective (HIV, HCV) and Oncology. These resulted in clinical candidates IDX320, Samatasvir and Uprifosbuvir. He has a proven ability to lead and deliver clinical candidates in a cross-functional and multi-cultural environment with a track record of delivering high quality candidate in a fast-paced environment. Proactive leadership with a high degree of priority setting, he recently completed is training by obtaining an Executive MBA with specialization in Lean 6 Sigma, Strategy and Leadership. Christophe is author and co-inventor of 30 + patents and peer review publications. In May 2019, Christophe joined Oncodesign as Drug Discovery Business Development Director.